Showing 821-830 of 1066 results for "".
- PrimeC Treatment for ALS Associated With Functional Improvements and Extended Survival According to 12-Month PARADIGM Datahttps://practicalneurology.com/news/primec-treatment-for-als-associated-with-functional-improvements-and-extended-survival-according-to-12-month-paradigm-data/2470524/New 12-month results from the PARADIGM clinical trial (NCT05357950) demonstrated a significant improvement in the rate of decline of Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for adults with ALS treated with PrimeC (ciprofloxacin/cele
- Nasal Therapy Associated with Pain Relief for Acute Migraine Including in Those with DTT Migrainehttps://practicalneurology.com/news/nasal-therapy-associated-with-pain-relief-for-acute-migraine-including-in-those-with-dtt-migraine/2470507/New analysis of data from the phase 3 SUMMIT study (NCT04940390) demonstrated that individuals with acute migraine treated with STS101 (dihydroergotamine [DHE] nasal powder; Satsuma Pharmaceuticals, Durham, NC) reported significant improvements in headache pain relief (PR), including those with d
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr
- Use of Andexanet Associated with Reduced Hematoma Volume Expansion, Increased Occurrence of Thrombotic Eventshttps://practicalneurology.com/news/use-of-andexanet-associated-with-reduced-hematoma-volume-expansion-increased-occurrence-of-thrombotic-events/2470498/According to results of a study published in The New England Journal of Medicine, people with intracerebral hemorrhage (ICH) treated with factor Xa (FXa) inhibitors who received andexanet showed reduced hematoma volume expansion compared with those who did not receive andexanet. The medi
- Wainua Treatment for hATTR-PN Associated with Improved Neuropathy Impairment and Quality of Life According to Long-Term Datahttps://practicalneurology.com/news/wainua-treatment-for-hattr-pn-associated-with-improved-neuropathy-impairment-and-quality-of-life-according-to-long-term-data/2470491/People with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) who were treated with Wainua (eplontersen; Astra Zeneca, Cambridge, UK; Ionis Pharmaceuticals, Carlsbad, CA) for 15 months showed improvements in quality of life (QoL) and neuropathy impairment, compared to historical
- Thrombectomy for Acute Stroke Patients with Large Infarcts Associated with Better Outcomes/Lower Mortality vs Medical Care Onlyhttps://practicalneurology.com/news/thrombectomy-for-acute-stroke-patients-with-large-infarcts-associated-with-better-outcomeslower-mortality-vs-medical-care-only/2470469/According to study results published in The New England Journal of Medicine, endovascular thrombectomy plus medical care resulted in better functional outcomes and lower mortality versus medical care alone but led to a higher incidence of intracerebral hemorrhage in patients wi
- Study Identifies Risks Associated with Intravenous Thrombolysis Therapy in Patients with Prior Intracerebral or Subarachnoid Hemorrhagehttps://practicalneurology.com/news/study-identifies-risks-associated-with-intravenous-thrombolysis-therapy-in-patients-with-prior-intracerebral-or-subarachnoid-hemorrhage/2470445/Study results presented at the American Academy of Neurology (AAN) 2024 Annual Meeting demonstrate that patients with a history of intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) who receive intravenous thrombolysis (IVT) for acute ischemic stroke have more than triple the risk of
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Novel Brain Cytoprotection Combination Therapy Associated with Improved Functional Outcomes in People with Acute Ischemic Strokehttps://practicalneurology.com/news/novel-brain-cytoprotection-combination-therapy-associated-with-improved-functional-outcomes-in-people-with-acute-ischemic-stroke/2470408/The use of Sanbexin (edaravone and dexborneol; Simcere, Nanjing, China) sublingual tablets, a formulation combining edaravone and dexborneol, was found to result in statistically significant improvements in functional outcomes for people with acute ischemic stroke (AIS) compared with placebo. The
- Gammagard Liquid Receives FDA Approval to Treat Disability and Impairment Associated with Chronic Inflammatory Demyelinating Polyneuropathyhttps://practicalneurology.com/news/gammagard-liquid-receives-fda-approval-to-treat-disability-and-impairment-associated-with-chronic-inflammatory-demyelinating-polyneuropathy/2470390/Gammagard Liquid (Immune Globulin Infusion [human] 10% solution; Takeda, Cambridge, MA) has been approved by the Food and Drug Administration (FDA) as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating